CARDIAC FUNCTIONS EVALUATED WITH TISSUE DOPPLER IMAGING IN CHILDHOOD CANCERS TREATED WITH ANTHRACYCLINES

REFERENCES

• Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol. 2000;12:146–152.
   PubMed Web of Science ®Google Scholar
• Boucek RJ. Mechanisms for anthracyline-induced cardiomyopathy: clinical and laboratory correlations. Prog Pediatr Cardiol. 1998;8:59–70.
   Google Scholar
• Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA. Persistant effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol. 1999;31:1435–1446.
   Google Scholar
• Senju N, Ikeda S, Koga S, . The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart Vessels. 2007;22:393–397.
   Google Scholar
• Ocal B, Oguz D, Karademir S, . Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol. 2002;23:522–527.
   Google Scholar
• Burke BE, Olson RD, Cusack BJ, Gambliel HA, Dillmann WH. Anthracycline cardiotoxicity in transgenic mice overexpressing SR Ca2+- ATPase. Biochem Biophys Res Commun. 2003;303:504–507.
   Google Scholar
• Sung RY, Huang GY, Shing MK, . Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol. 1997;60:239–248.
   PubMed Web of Science ®Google Scholar
• Yu WC, Lee WS, Huang WP, Wu CC, Lin YP, Chen CH. Evaluation of cardiac function by tissue Doppler echocardiography: hemodynamic determinants and clinical application. Ultrasound Med Biol. 2005;31:23–30.
   Google Scholar
• Sahn DJ, De Maria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography: results of echocardiographic measurements. Circulation. 1978;58:1072–1083.
   PubMed Web of Science ®Google Scholar
• Tavil Y, Ureten K, Ozturk MA, . The detailed assessment of left and right ventricular functions by tissue Doppler imaging in patients with familial Mediterranean fever. Clin Rheumatol. 2008;27:189–194.
   Google Scholar
• Rakowski H, Appleton C, Chan KL, (1996) Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiograhy. J Am Soc Echocardiogr. 9:736–760.
   PubMedGoogle Scholar
• Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995;26:396–404.
   Google Scholar
• Lewitt G. Cardioprotection. Br J Haematol. 1999;106:860–869.
   Google Scholar
• Lewitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol. 2004;124:463–468.
   Google Scholar
• Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr. 2001;160:607–610.
   PubMed Web of Science ®Google Scholar
• Moyssakis I, Moschos N, Triposkiadis F, . Left ventricular end-systolic stress/diameter relation as a contractility index and as a predictor of survival. Independence of preload after normalization for enddiastolic diameter. Heart Vessels. 2005;20:191–198.
   Google Scholar
• Steinherz LJ, Graham T, Hurwitz R, . Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics. 1992;89:942–949.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sander SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–815.
   PubMed Web of Science ®Google Scholar
• Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck Keck EW. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J. 1988;60:309–315.
   PubMedGoogle Scholar
• Marchandise B, Schroeder E, Bosly A, . Early detection of doxorubicin cardiotoxity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J.1989;118:92–98.
   PubMed Web of Science ®Google Scholar
• Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001;87:1120–1122.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62–69.
   PubMed Web of Science ®Google Scholar
• Bu’Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study. Pediatr Cardiol. 1999;20:252–263.
   PubMed Web of Science ®Google Scholar
• Bu’Lock FA, Mott MG, Oakhill A, . Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child. 1996;75:416–422.
   PubMed Web of Science ®Google Scholar
• Lee BH, Goodenday LS, Muswick GJ, . Alterations in left ventricular diastolic function with doxorubicin therapy. Am J Coll Cardiol. 1987;9:184–188.
   PubMed Web of Science ®Google Scholar
• Bruch C, Schmermund A, Marin D, . Tei index in patients with mild-to-moderate congestive heart failure. Eur Heart J. 2000;21:1888–1895.
   PubMed Web of Science ®Google Scholar
• Acil T, Wichter T, Stypmann J, . Prognostic value of tissue Doppler imaging in patients with chronic congestive heart failure. Int J Cardiol. 2005;103:175–181.
   PubMed Web of Science ®Google Scholar
• Choong CY, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol. 1987;10:800–808.
   PubMed Web of Science ®Google Scholar
• Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27:53–68.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD. The use of echocardiography and holter monitoring in the assessment of anthracycline-treated patients. In:Bricker JT, Green DM, Da′ngio GJ, eds. Cardiac Toxicity after Treatment for Childhood Cancer. New York:Wiley-Liss;1993:45–62.
   Google Scholar
• Kapusta L, Thijssen JM, Cuypers MH, . Assessment of myocardial velocities in healthy children using tissue Doppler imaging. Ultrasound Med Biol. 2000;26:229–237.
   PubMed Web of Science ®Google Scholar
• Kapusta L, Groot-Loonen J, Thijssen JM, DeGraaf R, Daniëls O. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol. 2003;41:426–435.
   PubMedGoogle Scholar
• Harada K, Tamura M, Toyono M, Yasuoka K. Comparison of the right ventricular Tei index by tissue Doppler imaging to that obtained by pulsed Doppler in children without heart disease. Am J Cardiol. 2002;90:566–569.
   PubMed Web of Science ®Google Scholar
• Rojo EC, Rodrigo JL, Pérez de Isla L, . Disagreement between tissue Doppler imaging and conventional pulsed wave Doppler in the measurement of myocardial performance index. Eur J Echocardiogr. 2006;7:356–364.
   Google Scholar
• Meinardi MT, Van Der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237–247.
   PubMed Web of Science ®Google Scholar
• Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544–1552.
   PubMed Web of Science ®Google Scholar
• Torti FM, Bristow MR, Howes AE, . Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745–749.
   PubMed Web of Science ®Google Scholar
• Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy-risk factors. Cancer. 1977;39:1397–1402.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, . Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717.
   PubMed Web of Science ®Google Scholar
• Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978;62:1381–1385.
   PubMedGoogle Scholar
• Lipshultz SE, Lipsitz SR, Mone SM, . Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–763.
   PubMed Web of Science ®Google Scholar
• Villani F, Comazzi R, Lacaita G, . Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother. 1985;2:93–97.
   PubMedGoogle Scholar